{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-102625","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.811677+00:00","generated_at":"2026-05-17T02:13:23.219261+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M","bullets":["At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.","Shareholders approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.","Ratification of Wolf & Company as independent auditor for fiscal year ending Sep 30, 2025 passed with 77.7M votes in favor.","Plan amendment doubles share pool for equity awards; approved by board Sep 19, 2025, now effective."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-102625","json":"https://secwatch.observer/filing/0001213900-25-102625.json","markdown":"https://secwatch.observer/filing/0001213900-25-102625.md","text":"https://secwatch.observer/filing/0001213900-25-102625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/0001213900-25-102625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/ea026265801-8k_citiusonc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:13:23.219261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}